All In Biotech

Drug Trial Radar · NCT01600105

Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)

Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests

Last checked: Nov 20, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

276

Actual

Start

Oct 2010

Primary completion

Jul 31, 2017

Study completion Jul 31, 2017

Sponsor

Lead sponsor
Bachir TaouliAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Patients with chronic liver disease are at high risk of developing liver scarring (fibrosis), with ultimate risks of cirrhosis and liver cancer that may require liver transplant. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR diffusion, perfusion and elastography) to assess the degree of liver damage in patients with chronic liver disease. These techniques combined could reach high diagnostic performance for detection of liver fibrosis; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.

Conditions

  • Chronic Liver Disease

Interventions

  • Perfusion MRIDrug

    1\) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PV FlowTime frame: Fasting State Scan (an average of 15 min) and Postprandial State Scan (an average of 15 min)
  2. PV VelocityTime frame: Fasting State Scan (an average of 15 min) and Postprandial State Scan (an average of 15 min)
  3. LS-MRE for Sub-Study ITime frame: Fasting State Scan (an average of 15 min) and Postprandial State Scan (an average of 15 min)
  4. True Diffusion Parameter (D)Time frame: Fasting State Multiparametric MRI Scan (an average of 60 min) Scan
  5. LS-MRE Fibrosis State for Sub Study IITime frame: Fasting State Multiparametric MRI Scan (an average of 60 min)
  6. LS-TETime frame: Fasting transient elastography, average duration 10 min
  7. MTTTime frame: Fasting State Multiparametric MRI Scan (an average of 60 min)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.